WO2024023746 - IMPROVED PRODUCTION OF CD39 VARIANTS
National phase entry:
Publication Number
WO/2024/023746
Publication Date
01.02.2024
International Application No.
PCT/IB2023/057614
International Filing Date
27.07.2023
Title **
[English]
IMPROVED PRODUCTION OF CD39 VARIANTS
[French]
PRODUCTION AMÉLIORÉE DE VARIANTS DE CD39
Applicants **
NOVARTIS AG
Inventors
AUSLAENDER, David
LEBESGUE, Nicolas
OBRDLIK, Petr
TAPPAREL, Joël Aloïs René
WAGNER, Nina
Priority Data
63/369,841
29.07.2022
US
63/512,316
07.07.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2340 | |
| EPO | Filing, Examination, Granting | 9294 | |
| Japan | Filing, Examination, Granting | 2124 | |
| South Korea | Filing, Examination, Granting | 2042 | |
| USA | Filing, Examination, Granting | 5340 |
Total:
21,140
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention pertains to the use of miRNA technology for improving recombinant production of CD39 or variants thereof in CHO cells. The miRNA is used for knockdown of the endogenous protein CCL2 of the CHO cells which is difficult to separate from CD39 or variants thereof during purification.[French]
La présente invention concerne l'utilisation de la technologie des miARN pour améliorer la production recombinante de CD39 ou de variants de celui-ci dans des cellules CHO. Le miARN est utilisé pour l'inactivation de la protéine endogène CCL2 des cellules CHO qui est difficile à séparer de CD39 ou de variants de celui-ci pendant la purification.